Want to see TSE:EPRX full AI Analyst Report?
Eupraxia Pharmaceuticals (EPRX) Income Statement
Eupraxia Pharmaceuticals Income Statement
Last quarter (Q2 2026), Eupraxia Pharmaceuticals's total revenue was $0.00. In Q2, Eupraxia Pharmaceuticals's net income was $-14.11M. See Eupraxia Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ -241.88K | $ -163.47K | $ -158.05K | $ -193.27K | $ -111.53K | |
| $ 38.86M | $ 25.54M | $ 28.37M | $ 23.38M | $ 18.38M | |
| Depreciation and Amortization | $ 241.88K | $ 171.72K | $ 117.41K | $ 190.42K | $ 111.53K |
| $ -38.86M | $ -23.42M | $ -28.20M | $ -22.14M | $ -21.96M | |
| $ -39.11M | $ -25.71M | $ -28.53M | $ -23.58M | $ -18.47M | |
| ― | $ 1.20M | $ -1.08M | $ -341.08K | $ -4.90M | |
| $ -39.26M | $ -24.51M | $ -28.93M | $ -23.92M | $ -23.37M | |
| $ -39.25M | $ -24.28M | $ -28.15M | $ -23.26M | $ -22.99M | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.05 | $ -0.72 | $ -1.19 | $ -1.21 | $ -1.61 |
| Diluted EPS | $ -1.05 | $ -0.72 | $ -1.19 | $ -1.21 | $ -1.61 |
| Weighted Average Shares Outstanding | 39.96M | 33.93M | 24.15M | 19.29M | 14.24M |
| Weighted Average Shares Outstanding (Diluted) | 39.96M | 33.93M | 24.15M | 19.29M | 14.24M |
Currency in CAD
